Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study

Table 2 Distribution of plasma human immunodeficiency virus-RNA levels

Weeks	HIV-RNA (copies/mL)	FDC	MTR	Total	Follow-up analysis	Overall analysis
	Total	80	163	243
0	NR	60	125	185	1P = 0.772
	< 20	20	38	58
24	NR	60	104	164	2P = 0.354; GOR 0.704 (95%CI: 0.403 to 1.229)	3P = 0.991; 4P = 0.366; GOR 0.956 (95%CI: 0.677 to 1.351); 5P = 0.298
	< 20	10	34	44
	20-50	8	15	23
	> 50	2	5	7
	Discontinued study drug	0	5	5
48	NR	56	100	156	2P = 0.828; GOR 0.996 (95%CI: 0.547 to 1.815)
	< 20	14	29	43
	20-50	5	7	12
	> 50	1	1	2
	Discontinued study drug	4	26	30
96	NR	53	92	145	2P = 0.310; GOR 1.385 (95%CI: 0.722 to 2.657)
	< 20	16	21	37
	20-50	4	4	8
	> 50	01	01	0
	Discontinued study drug	7	46	53

¹Pearson’s chi-square;

²Cochran-Armitage test for trend;

³Extended Mantel-Haenszel test for trend;

⁴Chi square test for heterogeneity;

⁵Chi square test for heterogeneity of GOR.¹Assumed 1 for Extended Mantel-Haenszel test for trend in overall analysis. GOR: Generalized odds ratio; HIV: Human immunodeficiency virus; MTR: Multi-tablet regimen; FDC: Fixed dose coformulation.